-
公开(公告)号:US10144738B2
公开(公告)日:2018-12-04
申请号:US15437618
申请日:2017-02-21
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: C07D487/04 , A61K31/4985
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, wherein A, A′ and A″ are independently O, C═O, etc.; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, etc.; R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), etc.; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US11926642B2
公开(公告)日:2024-03-12
申请号:US17365213
申请日:2021-07-01
Applicant: Pfizer Inc.
Inventor: Robert Steven Kania , Padmavani Bezawada , Emma Louise Hawking , Rohit Jaini , Samir Kulkarni , Matthew Nathan O'Brien Laramy , Jonathan Richard Lillis , Suman Luthra , Dafydd Rhys Owen , Klimentina Dimitrova Pencheva , Anil Mahadeo Rane , Matthew Forrest Sammons , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst , Jamison Bryce Tuttle , Robert Louis Hoffman
CPC classification number: C07F9/5728 , A61P31/14 , C07B2200/13
Abstract: The invention relates to compounds of formula I
wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.-
公开(公告)号:US20230339930A1
公开(公告)日:2023-10-26
申请号:US18004996
申请日:2021-07-07
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Martin Youngjin Pettersson , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Qingyi Yang
IPC: C07D417/14 , A61P31/14
CPC classification number: C07D417/14 , A61P31/14
Abstract: The invention relates to compounds of Formula I
wherein R1, R2, p, m, A, Z1, Z2, Z3 and Z4 are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.-
公开(公告)号:US20220257563A1
公开(公告)日:2022-08-18
申请号:US17660270
申请日:2022-04-22
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC: A61K31/403 , A61P31/14 , C07D403/12 , A61K31/427 , A61K31/401
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US10822341B2
公开(公告)日:2020-11-03
申请号:US16181596
申请日:2018-11-06
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: C07D487/04
Abstract: A compound compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein A, A′ and A″ are independently O, C═O, C—R′ or N—R″, where R′ and R″ may independently be H, amino, —NR7COR6, COR6, —CONR7R8, C1-C6 alkyl, or hydroxy(C1-C6 alkyl), and R″ may be present or absent, and is present where the rules of valency permit, and where not more than one of A, A′ and A″ is O or C═O; R0 and R are independently H, Br, Cl, F, or C1-C6 alkyl; R1 is H, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R2 is selected from the group consisting of H, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6 alkyl), phenyl(C1-C6 alkyl), formyl, heteroaryl, heterocyclic, —COR6, —OCOR6, —COOR6, —NR7COR6, —CONR7R8, and —(CH2)n—W, where W is cyano, hydroxy, C3-C8 cycloalkyl, —SO2NR7R8, and —SO2—R9, where R9 is C1-C6 alkyl, C3-C8 cycloalkyl, heteroaryl, or heterocyclic; wherein each of said alkyl, cycloalkyl, heterocyclic, or heteroaryl may be unsubstituted or substituted by halo, cyano, hydroxy, or C1-C6 alkyl; X is C—R3 or N, where R3 may be H or C1-C6 alkyl; R4 and R5 are independently H, amino, C1-C6 alkyl, or hydroxy(C1-C6 alkyl); R6, R7 and R8 are each independently H, C1-C6 alkyl, C1-C4 alkoxy(C1-C6 alkyl), or C3-C8 cycloalkyl, said C1-C6 alkyl is optionally substituted by halo, CN or hydroxy; or, R7 and R8 together with the atom bonded thereto form a 5- or 6-membered ring, said ring being optionally substituted by halo, hydroxy, CN, or C1-C6 alkyl; and, n is 0, 1, 2 or 3. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US20250099424A1
公开(公告)日:2025-03-27
申请号:US18917336
申请日:2024-10-16
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC: A61K31/403 , A61K31/401 , A61K31/427 , A61P31/14 , C07D403/12
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US11472809B2
公开(公告)日:2022-10-18
申请号:US17014533
申请日:2020-09-08
Applicant: Pfizer Inc.
Inventor: Matthew Frank Brown , Alpay Dermenci , Andrew Fensome , Brian Stephen Gerstenberger , Matthew Merrill Hayward , Dafydd Rhys Owen , Stephen Wayne Wright , Li Huang Xing , Xiaojing Yang
IPC: A61K31/4985 , C07D487/04
Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
-
公开(公告)号:US11452711B2
公开(公告)日:2022-09-27
申请号:US17660270
申请日:2022-04-22
Applicant: Pfizer Inc.
Inventor: Dafydd Rhys Owen , Matthew Richard Reese , Matthew Forrest Sammons , Jamison Bryce Tuttle , Patrick Robert Verhoest , Qingyi Yang
IPC: C07D403/12 , A61K31/403 , A61P31/14 , A61K31/427 , A61K31/401
Abstract: The invention relates to compounds of Formula I″ wherein R, R1, R2, R3, p, q and q′ are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
-
公开(公告)号:US11254668B2
公开(公告)日:2022-02-22
申请号:US16638271
申请日:2018-08-09
Applicant: Pfizer Inc.
Inventor: Brian Stephen Gerstenberger , Andrew Fensome , Dafydd Rhys Owen , Matthew Frank Brown , Matthew Merrill Hayward , Felix Vajdos , Li Huang Xing , Stephen Wayne Wright
IPC: C07D471/04 , C07D401/04 , C07D401/14 , C07D405/14 , C07D519/00
Abstract: A compound having the structure: or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of said compound or pharmaceutically acceptable salt, wherein variables are defined in the specification. Also provided are methods of treatment as Janus Kinase inhibitors and pharmaceutical compositions containing the compounds of the invention and combinations thereof with other therapeutic agents.
-
公开(公告)号:US20220017548A1
公开(公告)日:2022-01-20
申请号:US17365213
申请日:2021-07-01
Applicant: Pfizer Inc.
Inventor: Robert Steven Kania , Padmavani Bezawada , Emma Louise Hawking , Rohit Jaini , Samir Kulkarni , Matthew Nathan O'Brien Laramy , Jonathan Richard Lillis , Suman Luthra , Dafydd Rhys Owen , Klimentina Dimitrova Pencheva , Martin Youngjin Pettersson , Anil Mahadeo Rane , Matthew Forrest Sammons , Bradley Paul Sullivan , Andrew John Thiel , Martyn David Ticehurst , Jamison Bryce Tuttle , Robert Louis Hoffman
Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.
-
-
-
-
-
-
-
-
-